Suzanne Ackloo,Cheryl H. Arrowsmith,Fuqiang Ban,Christopher J. Barden,Hartmut Beck,Jan Beranek,Francois Berenger,Albina Bolotokova,Guillaume Bret,Marko Breznik,Emanuele Carosati,Irene Chau,Yu Chen,Artem Cherkasov,Dennis Della Corte,Katrin Denzinger,Aiping Dong,Sorin Draga,Ian Dunn,Kristina Edfeldt,Aled Edwards,Merveille Eguida,Paul Eisenhuth,Lukas Friedrich,Alexander Fuerll,Spencer Gardiner,Francesco Gentile,Pegah Ghiabi,Elisa Gibson,Marta Glavatskikh,Christoph Gorgulla,Judith Guenther,Anders Gunnarsson,Filipp Guseve,Evgeny Gutkin,Alexander Hillisch,Laurent Hoffer,Anders Hogner,John J Irwin,Olexandr Isayev,Aleksandra Ivanova,Celien Jacquemard,Austin J Jarrett,Jan H. Jensen,Dmitri Kireev,Julian Kleber,S. Benjamin Koby,David Koes,Ashutosh Kumar,Maria G. Kurnikova,Alina Kutlushina,Uta Lessel,Fengling Li,Fabian Liessmann,Sijie Liu,Wei Lu,Jens Meiler,Akhila Mettu,Guzel Minibaeva,Rocco Moretti,Connor J Morris,Chamali Narangoda,Theresa Noonan,Leon Obendorf,Szymon Pach,Amit Pandit,Sumera Perveen,Gennady Poda,Pavel Polishchuk,Kristina Puls,Vera Putter,Didier Rognan,Dylan Roskams-Edris,Matthieu Schapira,Christina Schindler,Francois Sindt,Vojtech Spiwok,Casper Steinmann,Rick L. Stevens,Valerij Talagayev,Damon Tingey,Oanh Vu,W. Patrick Walters,Xiaowen Wang,Zhenyu Wang,Gerhard Wolber,Clemens Alexander Wolf,Lars Wortmann,Carlos A. Zepeda,Kam Y. J. Zhang,Jixian Zhang,Shuangjia Zheng

Abstract:The CACHE challenges are a series of prospective benchmarking exercises meant to evaluate progress in the field of computational hit-finding. Here we report the results of the inaugural CACHE #1 challenge in which 23 computational teams each selected up to 100 commercially available compounds that they predicted would bind to the WDR domain of the Parkinson's disease target LRRK2, a domain with no known ligand and only an apo structure in the PDB. The lack of known binding data and presumably low druggability of the target is a challenge to computational hit finding methods. Seventy-three of the 1955 procured molecules bound LRRK2 in an SPR assay with KD lower than 150 μM and were advanced to a hit expansion phase where computational teams each selected up to 50 analogs each. Binding was observed in two orthogonal assays with affinities ranging from 18 to 140 μM for seven chemically diverse series. The seven successful computational workflows varied in their screening strategies and techniques. Three used molecular dynamics to produce a conformational ensemble of the targeted site, three included a fragment docking step, three implemented a generative design strategy and five used one or more deep learning steps. CACHE #1 reflects a highly exploratory phase in computational drug design where participants sometimes adopted strikingly diverging screening strategies. Machine-learning accelerated methods achieved similar results to brute force (e.g. exhaustive) docking. First-in-class, experimentally confirmed compounds were rare and weakly potent, indicating that recent advances are not sufficient to effectively address challenging targets.

What problem does this paper attempt to address?

The paper mainly addresses the following issues: ### Research Background and Objectives - **Research Background**: There are currently no known small molecule ligands for the WD40 repeat (WDR) domain in the Parkinson's Disease (PD) related protein LRRK2. The abnormal kinase activity of LRRK2 is associated with the pathogenesis of PD, and the WDR domain may be a new target for regulating LRRK2 function. - **Research Objectives**: To identify small molecule compounds that can bind to the LRRK2-WDR domain through Computational Hit-finding Experiments (CACHE Challenge #1). ### Issues Addressed - **Core Issue**: Develop a novel drug screening strategy aimed at finding small molecule compounds that can specifically bind to the LRRK2-WDR domain, providing new insights for the treatment of Parkinson's Disease. - **Specific Issues**: - Select potential ligand molecules from commercial libraries and predict whether they can bind to the central cavity of the LRRK2-WDR domain. - Experimentally validate the selected compounds, including initial screening (Hit Identification Phase, Round 1) and subsequent extended validation (Hit Expansion Phase, Round 2). - Compare the effectiveness of different computational methods and evaluate their performance when faced with challenging drug targets. ### Main Findings - The paper reports that 23 teams used different computational methods to screen 1955 compounds, of which 73 compounds showed binding ability to LRRK2-WDR in Surface Plasmon Resonance (SPR) experiments. - In the second round of experiments, 7 chemical series of small molecule compounds were further confirmed to bind to the LRRK2-WDR domain with affinities as low as 18 μM. - The successfully discovered compounds represent the first reported small molecules that can bind to LRRK2-WDR, providing valuable chemical starting points for subsequent drug development. - In the computational workflows, most teams used Machine Learning (ML) or Deep Learning (DL) methods, including generative design strategies, molecular dynamics simulations, and consensus docking techniques. In summary, this study successfully explored virtual screening methods for the LRRK2-WDR domain through CACHE Challenge #1 and validated the biophysical activity of the screened compounds, providing new directions for drug development for Parkinson's Disease.

CACHE Challenge #1: targeting the WDR domain of LRRK2, a Parkinson's Disease associated protein.

In silico screening of LRRK2 WDR domain inhibitors using deep docking and free energy simulations

Active Learning Guided Hit Optimization for the Leucine-Rich Repeat Kinase 2 WDR Domain Based on In Silico Ligand Binding Affinities

CACHE (Critical Assessment of Computational Hit-finding Experiments): A public-private partnership benchmarking initiative to enable the development of computational methods for hit-finding

The Fourth CACHE Challenge – A Comprehensive Drug Discovery Workflow to Discover Potential Inhibitors of the Tyrosine Kinase Binding Domain of Cbl-b

The First CACHE Challenge – Testing Diverse Virtual Screening Scoring Methods to Identify Potential LRRK2 Binders

Subpocket Similarity-Based Hit Identification for Challenging Targets: Application to the WDR Domain of LRRK2

The Third CACHE Challenge – Finding Ligands Targeting the Macrodomain of SARS-CoV-2 NSP3 Using AI-inspired and Knowledge-Based Approaches.

D3R grand challenge 2015: Evaluation of protein-ligand pose and affinity predictions

A Target Class Ligandability Evaluation of WD40 Repeat-Containing Proteins

A resource to enable chemical biology and drug discovery of WDR Proteins

Reaction-Based Enumeration, Active Learning, and Free Energy Calculations To Rapidly Explore Synthetically Tractable Chemical Space and Optimize Potency of Cyclin-Dependent Kinase 2 Inhibitors

D3R Grand Challenge 4: ligand similarity and MM-GBSA-based pose prediction and affinity ranking for BACE-1 inhibitors

D3R grand challenge 4: blind prediction of protein-ligand poses, affinity rankings, and relative binding free energies

Crowdsourced mapping of unexplored target space of kinase inhibitors

D3R Grand Challenge 3: blind prediction of protein-ligand poses and affinity rankings

From pixels to druggable leads: A CADD strategy for the design and synthesis of potent DDR1 inhibitors

Predicting binding poses and affinity ranking in D3R Grand Challenge using PL-PatchSurfer2.0

Identification of LRRK2 Inhibitors Through Computational Drug Repurposing.

Performance of HADDOCK and a simple contact-based protein-ligand binding affinity predictor in the D3R Grand Challenge 2

Continuous Evaluation of Ligand Protein Predictions: A Weekly Community Challenge for Drug Docking